SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

29 May 2023 Evaluate
Net sales declined -16.97%  to  Rs. 1998.40 million from Rs. 2406.90 millions.The Net Loss for the quarter ended March 2023 is Rs. -308.60 millions as compared to Net Profit of Rs. 104.60 millions of corresponding quarter ended March 2022Operating profit for the quarter ended March 2023 decreased to 158.40 millions as compared to 275.10 millions of corresponding quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 1998.40 2406.90 -16.97 8101.20 7257.30 11.63 8101.20 7257.30 11.63
Other Income 136.60 72.10 89.46 1378.90 1261.60 9.30 1378.90 1261.60 9.30
PBIDT 158.40 275.10 -42.42 1411.10 1326.20 6.40 1411.10 1326.20 6.40
Interest 57.00 29.20 95.21 185.20 109.90 68.52 185.20 109.90 68.52
PBDT 101.40 245.90 -58.76 1225.90 1216.30 0.79 1225.90 1216.30 0.79
Depreciation 113.70 92.60 22.79 432.50 369.10 17.18 432.50 369.10 17.18
PBT -12.30 153.30 -108.02 793.40 847.20 -6.35 793.40 847.20 -6.35
TAX 296.30 48.70 508.42 294.60 42.30 596.45 294.60 42.30 596.45
Deferred Tax 301.90 48.80 518.65 156.40 -100.50 -255.62 156.40 -100.50 -255.62
PAT -308.60 104.60 -395.03 498.80 804.90 -38.03 498.80 804.90 -38.03
Equity 159.30 159.30 0.00 159.30 159.30 0.00 159.30 159.30 0.00
PBIDTM(%) 7.93 11.43 -30.65 17.42 18.27 -4.68 17.42 18.27 -4.68

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×